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Background Aspirin inhibits colorectal carcinogenesis. In a randomised double-blind
placebo-controlled trial, daily soluble aspirin significantly reduced recurrence of
colorectal adenomas at 1-year follow-up. In this study the results of daily intake of
low-dose aspirin on polyp recurrence at 4-year follow-up are presented.Methods 272
patients (naive for chronic aspirin use) with colorectal adenomas were randomly
assigned to treatment with lysine acetylsalicylate 160 mg/day (n=73) or 300 mg/day
(n=67) or placebo (n=132) for 4 years. The primary endpoints were adenoma
recurrence and adenomatous polyp burden at year 4, comparing aspirin at either
dose with placebo. The same endpoints were also assessed at year 1 or 4 (last
colonoscopy performed for each patient). Results At the final year 4 colonoscopy the
analysis included 185 patients (55 receiving aspirin 160 mg/day, 47 aspirin 300
mg/day and 83 placebo). There was no difference in the proportion of patients with
at least one recurrent adenoma between patients receiving aspirin at either dose
and those treated with placebo (42/102 (41%) vs 33/83 (40%); NS) or in the
adenomatous polyp burden (3.1±5.8 mm vs 3.4±6.2 mm; NS). Also, the proportion of
patients with at least one advanced recurrent adenoma did not differ (10/182 (10%)
in the aspirin group vs 7/83 (7%) in the placebo group; NS). Conclusion Daily low-
dose aspirin decreased adenoma recurrence significantly at 1 year but not at year 4.
This discrepancy might be explained by a differential effect of aspirin according to
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